Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US8435523B2 · kind B2 · utility
17Cited by
16References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2010 |
| Grant date | May 7, 2013 |
| Priority date | — |
| Expiry date | Jul 16, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.